Marshall Wace LLP Has $999,000 Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Marshall Wace LLP increased its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 691.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 117,978 shares of the specialty pharmaceutical company's stock after acquiring an additional 103,072 shares during the quarter. Marshall Wace LLP owned about 0.24% of KalVista Pharmaceuticals worth $999,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Barclays PLC increased its holdings in shares of KalVista Pharmaceuticals by 418.5% in the third quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company's stock worth $778,000 after acquiring an additional 54,257 shares in the last quarter. Geode Capital Management LLC raised its holdings in KalVista Pharmaceuticals by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 830,984 shares of the specialty pharmaceutical company's stock worth $9,624,000 after buying an additional 24,713 shares during the period. JPMorgan Chase & Co. lifted its stake in KalVista Pharmaceuticals by 8.0% in the third quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company's stock valued at $262,000 after buying an additional 1,670 shares in the last quarter. Hennion & Walsh Asset Management Inc. acquired a new position in shares of KalVista Pharmaceuticals in the fourth quarter valued at approximately $634,000. Finally, SG Americas Securities LLC raised its holdings in shares of KalVista Pharmaceuticals by 10.0% during the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company's stock worth $123,000 after acquiring an additional 1,319 shares during the period.

KalVista Pharmaceuticals Trading Down 4.7 %

Shares of KALV traded down $0.62 during midday trading on Tuesday, reaching $12.48. The stock had a trading volume of 651,726 shares, compared to its average volume of 412,792. The firm has a market cap of $620.65 million, a PE ratio of -3.43 and a beta of 0.05. The firm has a 50 day simple moving average of $11.99 and a 200-day simple moving average of $10.42. KalVista Pharmaceuticals, Inc. has a one year low of $7.30 and a one year high of $15.50.

Analyst Upgrades and Downgrades

KALV has been the topic of a number of research reports. Jones Trading restated a "buy" rating and issued a $30.00 price target on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. JMP Securities began coverage on shares of KalVista Pharmaceuticals in a report on Friday, January 31st. They issued an "outperform" rating and a $19.00 price objective on the stock. Needham & Company LLC restated a "buy" rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a "strong-buy" rating in a research note on Friday, January 31st. Finally, HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $24.83.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par acquired 73,649 shares of the company's stock in a transaction on Friday, February 7th. The shares were purchased at an average price of $9.29 per share, for a total transaction of $684,199.21. Following the completion of the purchase, the insider now directly owns 5,086,445 shares of the company's stock, valued at approximately $47,253,074.05. This represents a 1.47 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Benjamin L. Palleiko sold 5,104 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total value of $50,121.28. Following the transaction, the chief executive officer now owns 278,855 shares of the company's stock, valued at $2,738,356.10. This represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders bought 202,786 shares of company stock worth $1,880,511 and sold 17,292 shares worth $184,625. 10.50% of the stock is currently owned by company insiders.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).